Passage BIO, Inc. — Director's Dealing 2022

Nov 18, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Passage BIO, Inc. (PASG)
CIK: 0001787297
Period of Report: 2022-09-15

Reporting Person: Toernsen Monika Maria (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-09-15	Common Stock	M	5000	—	Acquired	5000	Direct
2022-09-19	Common Stock	S	1681	$1.5105	Disposed	3319	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-09-15	Restricted Stock Unit	$	M	5000	Disposed	2031-07-18	Common Stock (5000)	Direct

Footnotes

F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F2: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F3: Each RSU represents a contingent right to receive one share of Issuer's common stock.

F4: 1/4 of the RSUs vested on September 15, 2022, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.